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Background: Fisher syndrome (FS) is characterised by a
triad of ophthalmoplegia, ataxia and areflexia. The lesion
sites responsible for ataxia and ophthalmoplegia in FS
require further exploration. The aim of this study was to
determine the involvement of the central nervous system
in FS using 18F-fluorodeoxyglucose-positron emission
tomography (FDG-PET).
Methods: Cerebral glucose metabolism in 10 patients
with FS was compared with that of 60 age and sex
matched normal controls using PET. For individual
analyses, 15 age and sex matched controls were selected
from the control group. Patients also underwent MRI of
the brain and measurement of serum anti-GQ1b antibody.
Results: Group analyses revealed increased metabolism
in the cerebellar vermis and hemispheres, pontine
tegmentum, midbrain tectum, left thalamus and right
inferior frontal cortex (p,0.001, uncorrected). In contrast,
the visual association cortices (Brodmann areas 18 and
19) showed decreased metabolism bilaterally. Individual
analyses disclosed hypermetabolism in the cerebellar
vermis or hemispheres (n = 7), inferior frontal cortex
(n = 5) and brainstem (n = 4, p,0.005, uncorrected). A
negative correlation between the cerebellar hypermeta-
bolism and the interval from symptom onset to PET
(r = 20.745, p = 0.013) was also found.
Hypermetabolism was normalised on follow-up PET with
an improvement in ophthalmoplegia and ataxia in one
patient.
Conclusions: These findings indicate involvement of the
central nervous system in FS, and the hypermetabolism in
the cerebellum and brainstem suggests an antibody
associated acute inflammatory process as a mechanism
of this autoimmune disorder.
Fisher syndrome (FS) is characterised by a clinical
triad of ophthalmoplegia, ataxia and areflexia.1 The
ocular signs range from isolated iridoplegia to
complete ophthalmoplegia.2 The antibody to gang-
lioside GQ1b is often present in the serum of
patients with FS.3–5 Patients may have antecedent
Campylobactor jejuni infection and the anti-GQ1b
antibody may show cross reactivity with surface
epitopes on C jejuni.6 The pathogenic role of anti-
GQ1b antibody remains to be elucidated.
However, ganglioside GQ1b is present in the
paranodal portion of human ocular motor nerves
and may be a target molecule in anti-GQ1b IgG
antibody associated ophthalmoplegia.4 7 In addi-
tion, the antibody activity also reflects the severity
of the ophthalmoplegia.8
The lesion sites responsible for ataxia and
ophthalmoplegia in FS require further explora-
tion.9–11 Although FS has been considered a variant
of Guillain–Barré syndrome, some authors reported
a cerebellar type of ataxia and supranuclear
ophthalmoplegia in FS and suggested additional
involvement of the central nervous system.12 13 In
view of a recent study on paraneoplastic cerebellar
degeneration, another immune mediated neuro-
logical disorder, which demonstrated cerebellar
hypermetabolism on positron emission tomogra-
phy (PET) during the acute phase,14 we performed
18F-fluorodeoxyglucose (FDG) PET in 10 patients
with FS and anti-GQ1b antibodies to determine
the involvement of the central nervous system and




Ten patients (seven men) with a diagnosis of FS
were recruited in the neuro-ophthalmological clinic
and ward of Seoul National University Bundang
Hospital from December 2005 to May 2007
(table 1). Patient age ranged from 19 to 71 years
(mean 47.8 (SD 18.7), median 50). The diagnosis of
FS was based on acute ophthalmoplegia, ataxia and
areflexia without other identifiable causes.
Measurements of anti-GQ1b antibody
Serum samples were obtained from nine patients
during the acute phase. The samples were analysed
for the presence of IgG antibodies against GQ1b
with an enzyme linked immunosorbent assay
(ELISA) at Specialty Laboratories Inc (Santa
Monica, California, USA). Control and patient
sera were incubated for 2 h in microtitre wells
precoated with gangliosides GQ1b. After washing
off any unbound substances, a horseradish perox-
idase labelled antibody mixed against human
antibody was added to the wells and incubated
for another 2 h. Following a second wash, a
substrate solution containing tetramethylbenzi-
dine was added to the wells. A blue colour
developed in proportion to the amount of anti-
ganglioside autoantibodies bound in the initial step
and the colour development was stopped by adding
an acidic stop solution, which turned the blue
solution to a yellow colour. The intensity of the
colour absorbance was measured at 450 nm. The
titres of antiganglioside autoantibodies were
expressed as ratios of a reference control. The
samples were considered positive when the anti-
body titre was above 20% of the reference value.15
Brain MRI
MRI was performed with a 1.5 T unit (Intera;
Philips Medical Systems, Best, The Netherlands)
using our imaging protocol (axial turbo spin echo
T2 weighted imaging and axial/sagittal spin echo
T1 weighted imaging) in all patients.16 The imaging
parameters were 4800/100 (repetition time (ms)/
echo time (ms)) for T2 weighted imaging and 500/
11 for T1 weighted imaging with a section
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thickness of 6 mm, a matrix size of 2566256 (interpolated to
5126512) and a field of view of 200–220 mm. MRIs were
assessed by two neuroradiologists who were blinded to the
purposes of this study.
Image acquisition and analyses of PET
Brain PET studies were done using an Allegro PET scanner
(Phillips Medical System, Cleveland, Ohio, USA).14 The intervals
from symptom onset to PET studies ranged from 2 to 87 days
(median 13) (table 1). One patient underwent initial PET 3 days
after symptom onset and follow-up PET 4 months later.
Patients had fasted for at least 4 h before the studies and were
administrated 185 MBq (5 mCi) of 18F-FDG intravenously.
Image preprocessing and statistical analysis were done using
SPM2 (Statistical parametric mapping 2, Institute of Neurology,
University College London, UK). All images were spatially
normalised to the standard template provided by SPM2 and
then smoothed using isotrophic Gaussian Kernel (FWHW
12 mm) to minimise noise and improve between subject spatial
alignment. Appropriate voxel by voxel statistical tests were used
to evaluate differences in glucose metabolism. Detailed methods
on data acquisition and processing have been reported
previously.14
Firstly, the metabolic abnormality in patients with FS was
tested as a group. For comparison, 60 healthy subjects (43 men,
mean age 50.1 (SD 14.9), range 24–71 years) without a previous
history of neurological disorders or major illnesses served as
normal controls. Regional glucose metabolism, which was
proportionally scaled to global uptake, was compared between
the patient and control groups after considering age as a
covariate. Then, metabolic abnormality in each patient was
individually assessed by comparing the patient’s scan with that
of 15 age and sex matched healthy subjects selected from the
control group. The difference was considered significant when a
cluster consisting of at least 100 contiguous voxels exceeded a
threshold height of p,0.001 (uncorrected for multiple compar-
ison) in group comparison and p,0.005 for individual analyses.
We did not perform the correction of partial volume effect.17
We also determined a possible correlation between metabolic
abnormalities and the interval from symptom onset to PET
study. Furthermore, after calculating mean uptake in the brain
regions which showed a significant correlation based on SPM
analyses using marsbar (http://marsbar.sourceforge.net), the
correlation between regional metabolism and intervals from
symptom onset was retested as a region of interest using
Spearman’s rank correlation in SPSS 13.0 (SPSS Inc., Chicago,
Illinois, USA).
All experiments followed the tenets of the Declaration of
Helsinki and informed consent was obtained after the nature
and possible consequences of the study had been explained to




Most patients developed ophthalmoplegia along with ataxia
and areflexia several days after upper respiratory infection or
diarrhoea (table 1). The symptoms and signs usually progressed
over several days to weeks. Ophthalmoplegia involved both eyes
in all patients but one (patient No 3) who showed limitations of
adduction, depression and elevation, and ptosis without
pupillary abnormality in the right eye, which mimicked pupil
sparing third cranial nerve palsy. Extraocular movements were
limited both horizontally and vertically in all patients but one
(patient No 8) who showed only limited abduction in both eyes.
Ptosis was observed in six and the pupils were involved in seven
patients (table 1).
Serum IgG anti-GQ1b antibodies were found in seven
patients (table 1). CSF examination was normal except for
mildly elevated protein (table 1). In spite of generalised
areflexia, nerve conduction studies were normal in all patients
but one (patient No 5) who had also suffered from diabetes.
Brain MRI did not show any abnormality which could explain
the patients’ symptoms and signs. In all patients, symptoms
and signs improved markedly within 6 months after symptom
onset.
PET findings
Group analyses revealed increased metabolism in the cerebellar
vermis, bilateral cerebellar hemispheres, pontine tegmentum,
midbrain tectum, right inferior frontal cortex (Brodmann area
47) and left thalamus (p,0.001, uncorrected) (table 2, fig 1A).
In contrast, the bilateral occipital cortices (Brodmann areas 18
and 19) showed decreased metabolism (fig 1A).
Individual analyses disclosed hypermetabolism in the cere-
bellar vermis or hemispheres in seven of the 10 patients
Table 2 Brain regions showing increased or decreased metabolism in patients with Fisher syndrome




Rt Cerebellum (posterior lobe) (22, 284, 232) 4.79 4.43 2474
Cerebellum (tonsil) (2,258,240) 3.73 3.53
Pons (8,244,236) 3.80 3.50
Lt Cerebellum (posterior lobe) (232,280,234) 4.30 4.03 1055
Lt Cerebellum (anterior lobe) (218,234,222) 3.96 3.74 219
Cerebellum (vermis) (0,256,216) 3.33 3.19
Midbrain (22,236,28) 3.49 3.34
Lt Thalamus (212,214,10) 4.06 3.82 130
Rt Inferior frontal cortex (BA 47) (44,34,220) 4.02 3.79 122
Decreased metabolism
Lt Occipital cortex (BA 18/19) (230, 290,24) 5.32 4.84 1169
Rt Occipital cortex (BA 18/19) (50,270,210) 5.25 4.79 461
*Location of peak expressed as x, y, z coordinates in the Montreal Neurological Institute space.
{Cluster size k represents the number of contiguous voxels (26262 mm3) at a height threshold of p,0.001 (uncorrected).
BA, Brodmann area; Lt, left; Rt, right.
Research paper
514 J Neurol Neurosurg Psychiatry 2009;80:512–517. doi:10.1136/jnnp.2008.154765
 group.bmj.com on December 23, 2009 - Published by jnnp.bmj.comDownloaded from 
(p,0.005, uncorrected) (table 1). Another patient (patient No 9)
showed a tendency towards increased metabolism in the
cerebellar hemisphere (p,0.01), and cerebellar metabolism
was normal in the remaining two patients (patient Nos 7 and
8) (table 1). Five patients also showed hypermetabolism in the
inferior frontal cortex (patient Nos 2, 5, 6, 8, and 9) and four
(patient Nos 1, 2, 8 and 10) in the brainstem. In addition, the
medial temporal lobe and precuneus were the infrequent sites of
hypermetabolism in individual patients. In contrast, five
patients (patient Nos 2, 4, 5, 6 and 7) exhibited hypometabolism
in the occipital cortices (table 1).
We also determined the effect of interval from symptom
onset to PET on regional metabolism, which exhibited a
negative correlation between the interval and cerebellar
hypermetabolism (max-Z = 4.10 at x, y, z = (16, 274, 248),
cluster k = 789 at p,0.005) (fig 1B). Spearman rank correlation
coefficient of the region based analysis was 20.746 (p = 0.013,
two tailed test).
One patient (patient No 1) performed the follow-up PET
study 4 months later when the ophthalmoplegia almost
resolved, and the follow-up PET showed normalisation of the
initial cerebellar hypermetabolism (fig 2).
DISCUSSION
In patients with FS, we found cerebellar and brainstem
hypermetabolism using PET. Patients also showed hypermeta-
bolism in the right inferior prefrontal cortex and left thalamus
while the occipital cortex exhibited decreased metabolism.
Interestingly, the initial cerebellar hypermetabolism decreased
markedly on follow-up PET in one patient, and analyses
disclosed a negative correlation between the cerebellar hyper-
metabolism and the intervals from symptom onset to PET
studies.
Anti-GQ1b antibody is present in up to 90% of patients with
FS.4 18 The GQ1b ganglioside is enriched in the paranodal regions
of the extramedullary oculomotor, trochlear and abducens
nerves, and anti-GQ1b activity reflects the severity of ophthal-
moplegia and cerebellar-type ataxia in FS,5 8 explaining the close
association with acute ophthalmoplegia.7 8 However, GQ1b
ganglioside is also found in the cerebellum, and serum anti-
GQ1b IgG antibodies from patients with FS or Guillain–Barré
with ophthalmoplegia and ataxia selectively stain the cerebellar
molecular layer.19 Furthermore, GQ1 ganglioside expression is
also found in the brainstem.
Previous reports have debated on whether the ataxia in FS is
due to a central or peripheral process (sensory ataxic neuro-
pathy).9 13 19 The hypermetabolic areas (cerebellar vermis, cere-
bellar hemispheres, pontine tegmentum and midbrain tectum)
observed in our patients are well correlated with the clinical
features of ataxia and ophthalmoplegia, and suggest that the
ataxia and ophthalmoplegia in FS may be of central origin, at least
in part. Previously, MRI also documented central lesions in FS.20 21
Patients with anti-GQ1b antibody may present with varying
combinations of ophthalmoparesis, ataxia, areflexia or altered
Figure 1 (A) Brain
18F-fluorodeoxyglucose-positron emission
tomography (FDG-PET) of patients with
Fisher syndrome showed increased
glucose metabolism in the cerebellum
(posterior cerebellar hemisphere, vermis,
tonsil), pontine tegmentum, midbrain
tectum, left thalamus and right inferior
frontal cortex. In contrast, both occipital
cortices (Brodmann areas 18 and 19)
exhibited hypometabolism. Brain
metabolism in patients was compared
with 60 age and sex matched healthy
controls. Significant voxels (p,0.001,
uncorrected, cluster k .100) in statistical
T maps were superimposed on the
standard MRI templates spatially
normalised into Montreal Neurological
Institute space. The number in the left
upper corner of each image indicates the
distance (mm) of each axial plane from
the bicommissural plane, and the colour
coding bar represents T scores. R, right;
L, left. (B) Hypermetabolism in the
cerebellar vermis (max-Z = 4.10 at x, y,
z = (16, 274, 248)) shows a negative
correlation with the interval from
symptom onset to FDG-PET study. The
correlation rho is = 20.746 (p = 0.013)
at two tailed test. Each point represents
an individual subject.
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sensorium.22 Anti-GQ1b IgG antibody is also found in approxi-
mately 60% of patients with Bickerstaff’s brainstem encephal-
itis which is characterised by consciousness disturbance and
upper motor neuron signs.23 24 These findings all support a
spectrum of an immune mediated disease involving both the
peripheral and central nervous system in anti-GQ1b antibody
syndrome,5 21 25–27 even though our patients did not show the
features of Bickerstaff’s brainstem encephalitis.
However, there has been no report on cerebellar hyper-
metabolism in FS while hypermetabolism of the central
nervous system has been documented in limbic encephalitis
and paraneoplastic cerebellar degeneration, another well
known autoantibody mediated disorder.14 28 The hypermeta-
bolism in those disorders has been attributed to inflamma-
tory changes, and stereotaxic biopsy in fact revealed
inflammation with lymphocytic infiltrations and reactive
gliosis in one patient.28
Our patients also showed a negative correlation between
cerebellar hypermetabolism and intervals from symptom onset
to PET studies. Furthermore, the initial cerebellar hypermeta-
bolism was normalised on follow-up PET in one patient. The
increased metabolism in the target brain areas is common
during the acute stage of leukoencephalitis of autoimmune or
infectious aetiologies.14 29 30 Furthermore, the hypermetabolism
may resolve or evolve into hypometabolism at a later stage,14
which also indicates that the increased metabolism during the
acute phase is related to an active inflammatory process.
Our patients also exhibited hypometabolism in the visual
association cortices (Brodmann areas 18 and 19). In view of the
diplopia which all patients suffered from because of ophthal-
moplegia, the hypometabolism in the visual association area
may indicate an adaptive functional suppression of the cortical
responses to deranged visual inputs. Previously, occipital
hypometabolism was also observed in patients with oculopala-
tal tremor, another disorder with impaired visual processing
caused by pendular nystagmus.31
The hypermetabolism observed in the right prefrontal/frontal
cortex and left thalamus requires comment. In view of the lack
of corresponding symptoms/signs, negative MRI, only slight
changes in CSF and inability of the antibody to access the brain
parenchyma, antibody mediated inflammation of all of these
regions seems unlikely as a mechanism of the hypermetabolism.
The frontal cortices are known to adjust locomotor perfor-
mance in response to altered environments.32 In FS, the diplopia
and ataxia may require more attention and intention in
adjusting locomotion and limb movements. This, in turn,
would give rise to hyperactivity in the frontal cortices. A similar
finding of sustained prefrontal hyperactivity is also observed
during ataxic gait in patients with infratentorial stroke,33 which
also suggests a compensatory mechanism for the impaired
locomotor control. The mechanism of thalamic hypermetabo-
lism is also unknown. As the thalamus serves as a relay station
for the sensory processing or cerebello-cortical projection,34
sensory deafferentiation or cerebellar hypermetabolism may
affect thalamic metabolism. However, as sensory stimuli
usually evoke thalamic activation,35 the possible sensory
deprivation in our patients with FS may not account for the
thalamic hypermetabolism. The bilateral cerebellar hypermeta-
bolism in our patients also does not readily explain the increased
metabolism in the left side only. Instead, the thalamic
hypermetabolism might be ascribed to a reciprocal interaction
with the occipital cortices. The occipital hypometabolism,
probably an adaptive response to deranged visual inputs, may
have been achieved by modulation of multimodal sensory
processing in the left thalamus.34 The activation–deactivation
pattern between the thalamus and occipital cortex has also been
observed in oculopalatal tremor31 and during the acute stage of
vestibular neuritis.36
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Figure 2 In patient No 1, cerebellar hypermetabolism during the acute phase (A) decreased markedly on follow-up 18F-fluorodeoxyglucose-positron
emission tomography (B) 4 months later. The colour scale indicates the regional uptake value normalised for whole brain. The same scale is used for
(A) and (B). R, right; L, left.
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